Healthcare
Pacira BioSciences, Inc.(PCRX)
Live Price
Offline$23.00
-1.54% today
1Y Change
-4.56%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $960.00M
- Revenue Growth
- +3.6%
- EPS Growth
- +107.4%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pacira BioSciences, Inc. (PCRX) is a Healthcare stock with a market cap of $960.00M and listed on NASDAQ. The stock last traded around $23.00 and down 4.6% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +3.6%, EPS growth of +107.4%, a dividend yield of 0.0%. What stands out right now is revenue +3.6%, EPS +107.4%, free cash flow -23.5% with operating margin 3.4% and ROIC 1.6%. Valuation already assumes a fairly strong business story at P/E 106.3 and price/sales 1.3. Stock Foundry combines PCRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.6% vs +7.6% peer median
Operating Margin
Below sector median
+3.4% vs +19.4% peer median
P/E
Above sector median
106.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3.6% and EPS at +107.4%, with operating margin around 3.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.8% | -0.2% | -2.3% |
2026 Feb 26, 2026 | -32.9% | -3.0% | +1.2% | +3.2% |
2025 Nov 6, 2025 | +7.7% | +4.5% | +11.9% | +13.7% |
Benchmark Edge
PCRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PCRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PCRX Max Drawdown
-29.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PCRX and SPY.
Company Overview
Pacira BioSciences, Inc.
NASDAQ Global Select
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
- Leadership
- Frank D. Lee
- IPO Date
- Feb 3, 2011
- Employees
- 788
- Street Address
- 5401 West Kennedy Boulevard
- Mailing
- Tampa, FL, 33609
- Region
- Tampa, FL, US
- Reporting Currency
- USD
- Investor Line
- 813 553 6680
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 106.3
- EV/EBITDA
- 8.6
- Price/Sales
- 1.3
- Price/Book
- 1.5
Growth
- Revenue
- +3.6%
- EPS
- +107.4%
- Free Cash Flow
- -23.5%
Profitability
- Gross Margin
- 60.2%
- Operating Margin
- 3.4%
- Net Margin
- 1.3%
- ROE
- 1.3%
- ROIC
- 1.6%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 4.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.